Core Viewpoint - PSB Holdings, Inc. reported a slight decrease in earnings per share for the third quarter of 2025 compared to the previous quarter, but a significant increase compared to the same quarter last year, reflecting improved net interest margins and operational efficiency [1][3]. Financial Performance - Earnings per diluted common share for Q3 2025 were $0.86, down from $0.89 in Q2 2025 but up from $0.69 in Q3 2024 [1]. - Net income for Q3 2025 was $3.5 million, compared to $3.6 million in Q2 2025 and $2.9 million in Q3 2024 [1]. - Net interest income increased by $617,000 to $11.3 million in Q3 2025, attributed to higher yields on loans and lower funding costs [5][13]. Balance Sheet and Asset Quality - Total assets decreased by $9.9 million to $1.50 billion at the end of Q3 2025 [5]. - Cash and cash equivalents decreased by $20.0 million to $37.4 million [5]. - Non-performing assets increased by $1.3 million to $17.0 million, representing 1.13% of total assets [8][5]. - Total deposits increased by $11.6 million to $1.19 billion [9]. Loan Portfolio - Net loans increased by $5.8 million, or 1%, to $1.12 billion [5]. - The loan portfolio remains diversified, with commercial real estate and construction loans making up 56.3% of gross loans [7]. Non-Interest Income and Expenses - Non-interest income decreased by $171,000 to $1.9 million, primarily due to lower mortgage banking income [5][16]. - Non-interest expenses increased by $613,000 to $8.8 million, mainly due to higher health insurance costs [5][17]. Capital and Equity - Tangible book value per common share increased by 10.0% to $29.05 compared to $26.41 a year earlier [12]. - The return on average tangible common equity was 12.14% for Q3 2025, down from 13.11% in Q2 2025 [11][27]. Management Commentary - The CEO highlighted the return of net interest margins to historical levels and the successful expansion into the Milwaukee region, which has provided good lending opportunities [3]. - The company has increased tangible capital by $9.0 million over the past year and expects to continue expanding capital in 2026 [3].

BETHLEHEM, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Embassy Bancorp, Inc. (OTCQX: EMYB) (the “Company”), the parent company of Embassy Bank For the Lehigh Valley (the “Bank”), announces that the Board of Directors has authorized the adoption of a stock repurchase program for up to $5 million of its outstanding common stock. The stock repurchase program will become effective October 31, 2025. This is Embassy Bancorp, Inc.’s first stock repurchase program. Repurchases under this program will be made in open mar ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics highlighting preclinical data that further illustrate the potential for ORIC-944, a potent and selective allosteric inhibitor of the polycomb repressive comple ...

Powered by SPD-SmartGlass Film invented by Research Frontiers and Produced by Gauzy, this First-of-its-Kind Retrofit Dimmable Glazing System Transforms Building Facades Orlando, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR), the inventor and licensor of patented SPD-Smart film light-control technology, and Advanced Impact Technologies Group (AIT Group), a fully-integrated premier manufacturer of advanced functional glass solutions, and licensee of Research Frontiers’ technolog ...

Core Insights - INVO Fertility has announced a strategic partnership with Heidi Health to integrate an AI-powered scribe platform at its Wisconsin Fertility Institute, aimed at enhancing patient care and reducing administrative burdens for clinicians [1][3]. Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [5]. - The company operates two INVO Centers in the U.S. and one IVF clinic, and it is engaged in the sale and distribution of its proprietary INVOcell technology, which allows fertilization and early embryo development to occur in vivo [5]. Technology Integration - The AI-powered tool from Heidi Health automates clinical documentation, allowing clinicians to spend less time on administrative tasks, thus reducing burnout and improving patient interaction [2][3]. - The integration of the AI scribe is expected to automate over two hours of daily administrative work for clinicians, significantly decreasing manual note-taking by up to 80% [3]. Patient Experience Enhancement - The partnership aims to elevate the patient experience at the Wisconsin clinic, ensuring that individuals feel supported throughout their treatment journey [4]. - The technology will enable specialists to focus more on patient care, building trust, and personalizing treatment plans [3][4].

Core Insights - BCB Bancorp, Inc. reported a net income of $4.3 million for Q3 2025, an increase from $3.6 million in Q2 2025 but a decrease from $6.7 million in Q3 2024 [1][14] - The company declared a quarterly cash dividend of $0.16 per share, payable on November 24, 2025 [2] - The CEO highlighted a profitable quarter with improved capital ratios and a strong liquidity position, alongside an expanding net interest margin [3] Financial Performance - Net interest income for Q3 2025 was $23.7 million, a slight increase from $23.1 million in Q2 2025, but a decrease from $23.0 million in Q3 2024 [40] - The net interest margin increased to 2.88% in Q3 2025 from 2.80% in Q2 2025 and 2.58% in Q3 2024 [8][17] - Total assets decreased by $246 million, or 6.8%, to $3.353 billion as of September 30, 2025, primarily due to strategic initiatives to enhance capital ratios [6] Asset Quality - The company recognized $16.9 million in net charge-offs during Q3 2025, significantly higher than $3.4 million in Q3 2024, largely due to a $12.7 million charge-off related to a cannabis loan [18][30] - Non-accrual loans totaled $93.5 million, or 3.31% of gross loans, at September 30, 2025, compared to $35.3 million, or 1.13%, a year earlier [31] Balance Sheet Highlights - Total deposits were $2.687 billion at September 30, 2025, a slight increase from $2.662 billion at June 30, 2025 [8][11] - The allowance for credit losses increased to $37.8 million, or 1.34% of gross loans, as of September 30, 2025, compared to $34.8 million, or 1.15%, at December 31, 2024 [9][19] - Stockholders' equity decreased by $5.5 million, or 1.7%, to $318.5 million at September 30, 2025, primarily due to a decline in retained earnings [13] Year-to-Date Performance - For the first nine months of 2025, the company reported a net loss of $498,000, a significant decline from a profit of $15.4 million in the same period of 2024 [23][42] - Net interest income for the first nine months of 2025 was $130.4 million, down 11.5% from $147.4 million in 2024 [24] - Non-interest income increased to $6.6 million for the first nine months of 2025, compared to $2.0 million in the same period of 2024 [27]

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall SurvivalFLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation ( ...

Core Insights - Waton Financial Limited is transitioning from a traditional securities brokerage to a financial and crypto digital asset enterprise focused on integrating artificial intelligence and financial technology [1][4] - The company aims to position itself as a leader in AI trading technology and digital asset innovation, showcasing its proprietary AI agent technology and TradingWTF app [3][4] Company Overview - Waton Financial Limited operates primarily through its subsidiaries in Hong Kong, offering services such as securities brokerage, asset management, and software licensing [5] - The company emphasizes a technology-driven and customer-centric approach to deliver innovative financial solutions [5] Leadership and Strategy - The leadership team at Waton combines expertise in innovation, strategic vision, and capital markets, which is essential for driving the company's evolution in both traditional finance and digital asset ecosystems [2] - Waton is forming transformative partnerships to enhance its growth and solidify its position as an innovator in global financial technology [2] Technological Advancements - The redesigned website highlights Waton's AI-driven trading architecture, which integrates with its digital asset ecosystem, including cryptocurrencies and tokenized assets [3] - The company has established a Crypto Advisory Board and obtained a Type 1 license for participation in virtual asset trading platforms, enhancing its digital infrastructure [3] Commitment to Innovation - Waton's updated website reflects its commitment to transparency and innovation in AI-powered investment solutions, aiming to redefine investment management through AI [4] - The company seeks to merge machine intelligence with traditional finance to deliver institutional-grade solutions that connect legacy systems with the digital asset revolution [4]

Core Insights - GBank Financial Holdings Inc. has partnered with boxing legend Mike Tyson to promote the GBank Visa Signature® Card, aimed at providing a secure and rewarding payment option for gaming and sports enthusiasts [2][3] Company Overview - GBank Financial Holdings Inc. is a bank holding company based in Las Vegas, Nevada, listed on the Nasdaq under the symbol "GBFH" [4] - The company operates a national payment and Gaming FinTech business, serving clients across the U.S. with a focus on the gaming and sports entertainment markets [4] - GBank is recognized as a top national SBA lender, operating in 40 states and providing a range of banking products and services [5] Product Details - The GBank Visa Signature® Card is designed to facilitate fast and secure transactions for gaming and sports applications while offering cash rewards [3] - The partnership with Mike Tyson will be supported by a national promotional campaign emphasizing the card's speed, security, and flexibility [3] Mike Tyson's Role - Mike Tyson, a former heavyweight boxing champion and cultural entrepreneur, is expected to bring energy and innovation to the partnership, appealing to customers who value these traits [3][6]

Richland, WA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced today that they have appointed Dr. John J. Smith, M.D., J.D., and his team at Hogan Lovells as the company’s lead regulatory advisors for its FDA Investigational Device Exemption (IDE) submission for RadioGel®. Dr. Smith, a board-certified diagnostic radiologist and former associate professor at Harvard Medical School, is widely recognized as one of the nation’s leading FDA regulatory consultants in the medical device sector. ...